Drawbridge Health, Inc.

Drawbridge Health, Inc. is innovating the blood sampling experience by developing advanced healthcare technologies, enhancing patient comfort and accessibility through at-home blood collection devices. Founded in 2015 and headquartered in Menlo Park, US, Drawbridge Health focuses on reinventing blood sampling methods. The company has completed three deals, the most recent one occurring on October 27, 2020.

Jerome Scelza and Lee McCracken currently serve as CEOs, steering the company towards growth and innovation in healthcare technology. Drawbridge Health specializes in reinventing the blood sampling experience through innovative healthcare technology. The company offers two primary products: NanoDrop and OneDraw. NanoDrop is a sterile, disposable capillary blood sampling device designed for at-home use, which employs a proprietary dual nano-lancet technology to facilitate virtually pain-free blood collection.

OneDraw streamlines the blood draw process by mitigating common challenges such as discomfort and the need for multiple visits, providing a cohesive and efficient solution for both patients and healthcare providers. The user-friendly nature of these products caters to a wide array of end users, including patients, clinics, healthcare systems, research institutions, laboratories, and long-term care facilities. Drawbridge Health primarily targets markets across the United States, where regulatory clearance from the FDA has positioned these products as first-of-their-kind devices for at-home blood sampling. Drawbridge Health generates revenue through the direct sale of its patented blood sampling products to healthcare providers, clinics, and end consumers.

The transactions typically involve B2B partnerships with healthcare institutions and direct-to-consumer sales for at-home use. As a result of these diverse channels, the company enhances the accessibility of its products, facilitating a smoother patient experience and encouraging greater participation in health management. The pricing structure for these offerings is aligned with industry standards for medical devices, ensuring affordability while promoting widespread adoption among consumers. The flagship products, NanoDrop and OneDraw, reflect the company's commitment to pioneering solutions in blood sampling, contributing to improved patient outcomes and operational efficiencies within the healthcare landscape.

In October 2020, Drawbridge Health raised an undisclosed amount in venture funding from new investor Toho Holdings. This funding is aimed at supporting the research and development of Drawbridge Health's blood collecting devices. The company plans to introduce new products designed to enhance the blood sampling experience and expand its market presence beyond the United States, although specific regions and timelines for these expansions have not been disclosed.